Synlogic, Inc. (SYBX): history, ownership, mission, how it works & makes money

A Brief History of Synlogic, Inc. (SYBX)

Foundation and Early Years

Synlogic, Inc. was founded in 2014, emerging as a synthetic biotics company focused on harnessing the potential of engineered microbes to treat diseases. The company is headquartered in Cambridge, Massachusetts.

Corporate Developments

In March 2015, Synlogic completed a $15 million Series A financing round. Following this, in February 2016, the company announced a partnership with AbbVie for the development of engineered probiotics for the treatment of inflammatory bowel disease.

Public Offering

On July 25, 2017, Synlogic went public with its initial public offering (IPO), raising approximately $75 million. The shares were priced at $16 each.

Clinical Trials and Programs

Synlogic's lead program targets urea cycle disorder (UCD) with a product candidate known as SYB-201. Clinical trials for this product began with a Phase 1b trial in 2019 to evaluate its safety and efficacy.

Recent Developments

In 2020, Synlogic reported a net loss of $35.4 million, highlighting the expenditures associated with clinical trials and continued research.

Strategic Partnerships

In March 2021, Synlogic entered into a partnership with GSK to co-develop a rare disease therapy, providing the company with an additional $40 million in funding and potential milestone payments.

Financial Performance

For the year ended December 31, 2021, Synlogic reported revenues of $7.0 million, compared to $3.2 million in 2020. The operating expenses for 2021 were approximately $52 million.

Current Status

As of October 2023, Synlogic continues to advance its pipeline, with multiple programs in various phases of clinical trials including therapies for metabolic and autoimmune disorders.

A Who Owns Synlogic, Inc. (SYBX)

Ownership Structure

As of the latest data, Synlogic, Inc. (SYBX) has a diverse ownership structure that includes institutional investors, retail shareholders, and company insiders. The detailed breakdown of ownership is as follows:

Major Institutional Shareholders

Several institutional investors hold significant portions of Synlogic, Inc.'s stock. Below are the major institutional shareholders along with their respective holdings:

Insider Ownership

Insider ownership plays a crucial role in the governance of Synlogic, Inc. Below are key insider shareholders and their holdings:

Recent Stock Performance

Synlogic, Inc. has experienced notable fluctuations in its stock price. The following data highlights the recent stock performance:

Recent Financials

The latest financial metrics for Synlogic, Inc. are provided below:

Current Share Price and Trading Volume

The current share price of Synlogic, Inc. and trading volume are vital for understanding market dynamics:

Synlogic, Inc. (SYBX) Mission Statement

Overview

Synlogic, Inc. is a biotechnology company focused on the development of synthetic biotic therapies. The company's mission is to create innovative, genetically engineered organisms that can treat diseases by restoring function or providing new activities in the human body.

Core Values

• Innovation: Commitment to pioneering synthetic biology.
• Collaboration: Partnering with stakeholders to enhance therapeutic potential.
• Excellence: Striving for the highest standards in research and development.
• Patient Focus: Prioritizing patient outcomes in every initiative.
• Sustainability: Maintaining ethical practices and environmental responsibility.

Strategic Goals

Synlogic aims to leverage its proprietary technology to create a pipeline of therapies for rare and serious diseases. Recent strategic goals include:

• Advancing pipeline candidates into clinical trials.
• Expanding partnerships with pharmaceutical companies.
• Enhancing regulatory communication and achieving high standards for compliance.

Financial Performance

As of the latest quarter, Synlogic reported the following financial figures:

Recent Developments

In 2023, Synlogic announced significant milestones, including:

• Initiation of Phase 2 clinical trials for SYBX101.
• Collaboration with AbbVie to develop novel therapies.
• Presentation of data at the American Society of Gene & Cell Therapy (ASGCT) conference.

Pipeline Overview

Synlogic’s pipeline includes various promising candidates across multiple indications:

Investment and Collaboration

As of Q3 2023, Synlogic has secured funding from various sources:

• Public Offerings: $25 million raised in 2023.
• Grants: $3 million from the National Institutes of Health (NIH).
• Partnerships: Strategic alliances with multiple biotechnology firms.

Long-term Vision

Synlogic envisions a future where synthetic biotics transform the treatment landscape for patients with genetic and metabolic diseases, thereby enabling better health outcomes and improved quality of life.

How Synlogic, Inc. (SYBX) Works

Business Model

Synlogic, Inc. operates as a clinical-stage biotechnology company focusing on engineered microorganisms to treat metabolic and rare diseases. Their proprietary platform, called Synlogic Engineered Therapeutics, is designed to develop therapies using modified live bacteria.

Current Pipeline

As of October 2023, Synlogic has several key programs in its development pipeline:

• SYB102 for Phenylketonuria (PKU) - Phase 2 Trials
• SYB201 for acetaminophen overdose - Phase 1 Trials
• SYB301 for Inborn Errors of Metabolism - Preclinical

Financial Overview

For the fiscal year ended December 31, 2022, Synlogic reported the following financial figures:

• Revenue: $5.2 million
• Net Loss: $48.4 million
• Cash and Cash Equivalents: $50 million
• Research and Development Expenses: $34 million
• General and Administrative Expenses: $14 million

Market Position

As of October 2023, Synlogic, Inc. had a market capitalization of approximately $200 million. The company is listed on the NASDAQ under the ticker symbol SYBX.

Collaborations and Partnerships

Synlogic has formed strategic alliances with:

• Pfizer, focused on immuno-oncology
• AbbVie, focusing on a combination approach for metabolic diseases

Recent Developments

In August 2023, Synlogic announced an agreement with a leading pharmaceutical company to develop a combination therapy aimed at improving treatment effectiveness for metabolic disorders. The financial terms of the agreement are not publicly disclosed.

How Synlogic, Inc. (SYBX) Makes Money

Revenue Generation Model

Synlogic, Inc. primarily generates revenue through collaborations and partnerships with pharmaceutical companies, as well as through grant funding and public financing. The company’s innovative approach in synthetic biology is aimed at creating engineered living medicines to treat a variety of diseases.

Collaboration Agreements

The majority of Synlogic's financial inflows stem from collaboration agreements with larger pharmaceutical firms. For example, in 2021, Synlogic entered into a partnership with AbbVie to develop therapies targeting autoimmune diseases, which included an upfront payment of $30 million and potential milestone payments amounting to $640 million.

Grant Funding

Synlogic has been awarded numerous grants from various institutions, which serves as a crucial component of their funding strategy.

Equity Financing

Synlogic also utilizes equity financing strategies to raise capital for its operations. As of October 2023, the company has raised approximately $160 million through various equity offerings since its IPO in 2017.

Revenue from Product Development

The company is focused on developing its proprietary therapies, specifically:

• Synlogic's lead product candidate, SYBX-101, aims to treat urea cycle disorders.
• Another candidate, SYBX-201, is being developed for treating inflammatory bowel disease.

Revenue from these product candidates is contingent on successful clinical development and eventual commercialization.

Financial Performance Overview

As of the latest fiscal report, Synlogic's financial metrics include:

Market Opportunities

The potential market for Synlogic’s engineered living therapies spans multiple therapeutic areas, including:

• Metabolic diseases
• Oncology
• Autoimmune disorders

This diversified focus positions Synlogic to capitalize on emerging markets and unmet medical needs, contributing to its revenue expansion.

Intellectual Property and Licensing

Synlogic's intellectual property (IP) portfolio enhances its value proposition, allowing the company to license its technologies and products to other biotech and pharmaceutical firms. In 2022, the company obtained 15 patents related to its core technologies, reinforcing its competitive advantages and opening additional revenue channels.

Conclusion

Synlogic, Inc.'s multifaceted revenue strategy incorporates collaboration agreements, grant funding, equity financing, product development, and licensing of their intellectual property, marking it as a significant player in the biotech industry.